Patent · US Active

Methods of treating an eye disorder

US11912784B2 · kind B2 · utility

1Cited by
308References
43Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 9, 2020
Grant dateFeb 27, 2024
Priority date
Expiry dateOct 9, 2040

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/545
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and/or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate that includes a polymeric moiety that extends the half-life/effectiveness/properties of the antibody when administered to a subject. A method of the present disclosure includes administering one or more doses of an anti-VEGF antibody conjugate to a subject (e.g., human or other mammalian patient) in need of treating an eye disorder, where the anti-VEGF antibody conjugate may be administered less frequently than a standard anti-VEGF therapy to treat the eye disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.